Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21680497 | 0.98 | TDP1 (0.68) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1629516 | 0.94 | TDP1 (0.62) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL25304212 | 0.90 | TDP1 (0.56) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL134329 | 0.90 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL136815 | 0.90 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL343629 | 0.90 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL3025184 | 0.90 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL137629 | 0.90 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL5162656 | 0.90 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL343419 | 0.90 | TDP1 (0.85) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793947-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2021-02-03 | — | — | EP | disclosed |
| US-10675359-B2 | Enzymatic conjugation of antibodies | INNATE PHARMA (FR) | 2020-06-09 | — | — | US | disclosed |
| EP-3564259-A2 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | Innate Pharma (FR) | 2019-11-06 | — | — | EP | disclosed |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | INNATE PHARMA (FR) | 2019-10-08 | — | — | US | disclosed |
| US-20190169601-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | INNATE PHARMA (FR) | 2019-06-06 | — | — | US | disclosed |
| EP-2872894-B1 | SCREENING OF CONJUGATED ANTIBODIES | INNATE PHARMA (FR) | 2019-04-17 | — | — | EP | disclosed |
| EP-3240573-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2019-03-20 | — | — | EP | disclosed |
| EP-2793949-B1 | ENZYMATIC CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2018-08-22 | — | — | EP | disclosed |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | INNATE PHARMA (FR) | 2018-07-31 | — | — | US | disclosed |
| US-20180193476-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2018-07-12 | — | — | US | disclosed |
| US-20150165064-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | ARARIS BIOTECH LTD (CH) | 2015-06-18 | — | — | US | disclosed |
| EP-2872894-A2 | SCREENING OF CONJUGATED ANTIBODIES | Innate Pharma (FR) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014202775-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2014-12-24 | — | — | WO | disclosed |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2793947-A2 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | Innate Pharma (FR) | 2014-10-29 | — | — | EP | disclosed |
| EP-2793949-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | Innate Pharma (FR) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014072482-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | INNATE PHARMA (FR) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014009426-A2 | SCREENING OF CONJUGATED ANTIBODIES | INNATE PHARMA (FR) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013092983-A2 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092998-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675359-B2 | Enzymatic conjugation of antibodies | DNPEP, MPO, FCGR3B | TDP1 1163/4885MAOA 40/4885MAOB 61/4885 |
| US-20180193476-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | DNPEP, MPO, FCGR3B | TDP1 1163/4885MAOA 40/4885MAOB 61/4885 |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | DNPEP, ENPEP, PEPD | TDP1 696/4885MAOA 85/4885MAOB 120/4885 |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | TGM2, TGM3, TGM6 | TDP1 1188/4885MAOA 930/4885MAOB 1084/4885 |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | DNPEP, MPO, FCGR3B | TDP1 1163/4885MAOA 40/4885MAOB 61/4885 |
| US-20190169601-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM6 | TDP1 1188/4885MAOA 930/4885MAOB 1084/4885 |
| US-20150165064-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | TDP1 696/4885MAOA 85/4885MAOB 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.